Wednesday, November 15, 2017 9:34:49 AM
The Issuer is authorized to issue 2,000,000,000 shares of common stock. As of September 30, 2017, the issuer had 524,524,856 shares of common stock outstanding.
Revenue increased to $132,313 compared to $65,407 last year.
As of September 30, 2017, the Company has a total of $427,861 Convertible Note payable owed to unrelated third parties. This notes are convertible into common shares of the Issue, due on demand and bear no interest.
As of September 30, 2017, the Company paid advances totalling an aggregate of $262,400, the advances are unsecured, non-interest bearing and is due upon demand giving 30 days written notice to the borrower and remains as an accounts on the company’s books.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM